Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
977 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (401)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | recruiting | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases(ECLIPSE) | recruiting | Phase 3 | 412 | Rakuten Medical, Inc.INDUSTRY | 3 |
| Oct 15, 2025 |
| clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT05945875 | Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer | recruiting | Phase 1 | 40 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06664151 | A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision | recruiting | Early Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06006169 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 186 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07111455 | Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy | recruiting | — | 32 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03396718 | De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas(DELPHI) | recruiting | N/A | 304 | Technische Universität DresdenOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05582122 | SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers(SURVEILLE-HPV) | recruiting | Phase 2 | 420 | UNICANCEROTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06469008 | A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06536257 | Personalised Immunotherapy Platform(PIP-PREDICT) | recruiting | — | 1,000 | Melanoma Institute AustraliaOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07180901 | Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer(PRONTO-HN) | recruiting | N/A | 85 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07010692 | Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment | recruiting | Phase 1 / Phase 2 | 100 | Bruce Robinson, MDOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06601309 | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC(ESCC) | recruiting | Phase 2 | 90 | Fujian Medical University Union HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07064330 | Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.(NGF-GRACE) | recruiting | — | 30 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06686342 | PDO Based Drug Sensitive Test in R/M HNSCC | recruiting | — | 100 | Huashan HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07152678 | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma(BRIGHT-ESCC) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06509568 | Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） | recruiting | Phase 2 | 92 | Zhejiang Cancer HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07133958 | A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC | recruiting | — | 35 | Zhujiang HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT05446467 | Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC | recruiting | Phase 2 | 80 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07131566 | Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer | recruiting | — | 500 | Lars Olaf CardellOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06700070 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | recruiting | Early Phase 1 | 12 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07105592 | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 68 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03649048 | Low-Dose Weekly vs High-Dose Cisplatin(RADIO) | recruiting | N/A | 100 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06307015 | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)(DE-RADIATE) | recruiting | N/A | 25 | Royal North Shore HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | recruiting | — | 170 | National Cancer Institute, NaplesOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07088354 | Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy(DL-ESCC) | recruiting | — | 300 | Tongji HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07080437 | An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | — | 40 | Three Gorges Hospital of Chongqing UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06935188 | Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC | recruiting | Phase 2 | 98 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05774483 | Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative(SECOND N0) | recruiting | N/A | 508 | Tata Memorial HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07055841 | Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Xiuping DingOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05272696 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | recruiting | Phase 2 | 86 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06061705 | Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies(iMonitORL) | recruiting | N/A | 100 | Fondation Hôpital Saint-JosephOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06384053 | Skin Cancer and Hyperthermia and Radiotherapy(SAHARA) | recruiting | N/A | 100 | Kantonsspital Winterthur KSWOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07016724 | Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer | recruiting | Phase 2 | 208 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05108090 | Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | recruiting | N/A | 94 | Indiana UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06005324 | Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer | recruiting | Phase 1 | 36 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06446726 | Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Sichuan UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06494995 | AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy | recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 20, 2025source: clinicaltrials